



SHAREABLE PDF

New Xpert MTB/XDR: added value and future in the field

Arnold Bainomugisa¹, Christopher Gilpin², Christopher Coulter¹ and Ben J. Marais³

Affiliations: ¹Queensland Mycobacterium Reference Laboratory, Pathology Queensland, Brisbane, Australia. ²International Organization for Migration, Geneva, Switzerland. ³The Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI), University of Sydney, Sydney, Australia.

Correspondence: Arnold Bainomugisa, Queensland Mycobacterium Reference Laboratory, Pathology Queensland, Royal Brisbane and Women Hospital complex, Block 7, Level 5, Brisbane, Australia. E-mail: Arnold.bainomugisa@health.qld.gov.au



@ERSpublications

Xpert MTB/XDR is a new rapid molecular test for drug resistant tuberculosis <https://bit.ly/3l2t4op>

Cite this article as: Bainomugisa A, Gilpin C, Coulter C, *et al.* New Xpert MTB/XDR: added value and future in the field. *Eur Respir J* 2020; 56: 2003616 [<https://doi.org/10.1183/13993003.03616-2020>].

This single-page version can be shared freely online.

The recent launch of the new Xpert MTB/XDR assay (Cepheid Inc., Sunnyvale, CA, USA) by the Foundation for Innovative New Diagnostics [1] was widely welcomed by the tuberculosis (TB) community, given the critical need for new and better diagnostics to guide the treatment of drug resistant tuberculosis (DR-TB). Xpert MTB/XDR detects resistance to isoniazid (target genes: *inhA* promoter, *katG*, *fabG1*, *oxyR-aphC* intergenic region), ethionamide (*inhA* promoter), fluoroquinolones (*gyrA* and *gyrB*), and second-line injectables (*rrs* and *eis* promoter) and is positioned as an add-on or “reflex test” in patients with rifampicin resistance detected by Xpert MTB/RIF or Ultra [2, 3].